β-hydroxybutyrate enhances structural repair but not early functional recovery in septic muscle: implications for phased interventions in sepsis- associated ICUAW
Exogenous β-hydroxybutyrate accelerates early structural regeneration of skeletal muscle in septic mice by activating the Wnt signaling pathway, yet it fails to improve early functional recovery, highlighting a dissociation between myogenesis and neuromuscular function that suggests a need for phased interventions in sepsis-associated ICUAW.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
When a person survives a severe infection like sepsis, they often face a second, silent battle: their muscles waste away rapidly, leaving them too weak to breathe or move. This condition, known as intensive care unit-acquired weakness, is not just about muscles shrinking; it is a complex failure of the body's ability to rebuild itself. In a healthy body, tiny reservoirs of stem cells called satellite cells sit dormant beneath muscle fibers, waiting to spring into action when damage occurs. They wake up, multiply, and then transform into new muscle tissue to repair the injury. However, in the chaos of sepsis, the body's inflammatory storm seems to confuse these repair crews, halting the rebuilding process even after the infection is under control. Scientists have long searched for a way to jumpstart this stalled recovery, looking for a signal that could tell the muscle to start growing again. One promising candidate is a substance the body naturally produces during fasting or intense exercise, a fuel source that also carries instructions for cell repair.
Researchers set out to test whether giving this substance, known as beta-hydroxybutyrate, to mice with sepsis could help their muscles heal. They induced a severe infection in the animals and then divided them into groups, giving some a low dose, some a medium dose, and some a high dose of the substance, while others received only a saltwater solution. The goal was to find the right amount that would help without causing harm. The results showed that a medium dose was the sweet spot. Mice receiving this amount had significantly less inflammation in their blood and retained more of their lean muscle mass compared to those who received only the saltwater. Interestingly, the high dose did not offer extra benefits and actually showed a trend toward higher death rates, suggesting that too much of a good thing could be dangerous in this context.
Over the course of ten days, the team watched how the muscles changed. They found that the mice treated with the medium dose of the substance recovered the physical size of their muscle fibers much faster. By the fifth day, the muscle fibers in these mice were visibly larger and more robust than those in the untreated group. To understand how this happened, the scientists looked inside the muscle tissue at the satellite cells. They discovered that the treated mice had a much larger pool of these repair cells. Specifically, there were more cells ready to wake up and multiply, and by the fifth day, there was a surge of cells that had already begun the final stage of turning into new muscle. This suggests the substance acted like a catalyst, pushing the repair cells through their necessary steps of waking up, dividing, and maturing.
The researchers then wanted to know exactly how this substance was sending these instructions. They suspected it was working through a specific communication pathway inside the cells known as the Wnt signaling pathway, which is a master regulator for how muscle stem cells decide their fate. To test this, they gave a group of mice the substance along with a chemical blocker that stops the Wnt pathway from working. The result was clear: when the pathway was blocked, the benefits of the substance vanished. The mice lost their extra muscle mass, and the surge of repair cells disappeared. This confirmed that the substance works by turning on this specific cellular switch to drive muscle regeneration.
However, the story had a surprising twist. While the muscles in the treated mice were physically larger and structurally sound, the mice did not get stronger in the way a human would notice. When the researchers tested how hard the mice could grip with their front paws, there was no difference between the treated group and the untreated group. The muscles had rebuilt their structure, but they had not yet regained their full function. This reveals a crucial gap in the recovery process: the body can rebuild the bricks of a wall long before the wall can hold weight. The new muscle fibers were there, but they were not yet fully connected to the nerves that tell them to move, or they had not yet matured enough to contract powerfully.
This finding suggests that recovering from severe muscle weakness is not a single event but a series of phases. The first phase is structural, where the body rebuilds the tissue, and the second is functional, where the tissue learns to work again. The substance studied here is excellent at speeding up the first phase, helping the body get past the initial damage quickly. But it does not solve the second phase on its own. For a patient to truly recover their strength, they may need a different kind of help later on, perhaps one that focuses on reconnecting the nerves or training the new muscle to work. The study concludes that while this substance offers a powerful tool to jumpstart muscle repair in the early days of recovery, the journey to full strength requires a longer, more complex strategy that addresses both the building of the muscle and the reconnection of its control systems.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.